US 12,410,258 B2
Antibodies capable of binding to OX40, variants thereof and uses thereof
Kristel Kemper, Utrecht (NL); Maarten van der Kroef, Utrecht (NL); Dennis Verzijl, Utrecht (NL); Andrea Gorlani, Utrecht (NL); Pauline Linda de Goeje, Utrecht (NL); Lars Guelen, Utrecht (NL); David Satijn, Utrecht (NL); Esther C. W. Breij, Utrecht (NL); Ugur Sahin, Mainz (DE); Sina Fellermeier-Kopf, Mainz (DE); and Maren Köhne, Mainz (DE)
Assigned to Ganmab A/S, Valby (DK); and BioNTech SE, Mainz (DE)
Filed by Genmab A/S, Valby (DK); and BioNTech SE, Mainz (DE)
Filed on May 10, 2024, as Appl. No. 18/660,672.
Claims priority of application No. 23173143 (EP), filed on May 12, 2023; and application No. 23213531 (EP), filed on Nov. 30, 2023.
Prior Publication US 2024/0376221 A1, Nov. 14, 2024
Int. Cl. C07K 16/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/42 (2006.01)
CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); C07K 16/4241 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)] 23 Claims
 
1. An antibody capable of binding to human OX40, wherein the antibody comprises a VH having the sequence as set forth in SEQ ID NO: 20 and a VL having the sequence as set forth in SEQ ID NO: 21.